Table 4.

Distribution of the patients according to the Paris classification, complications observed and TACI mutation results

Patient	Paris	TACI	Complication
Z.Ç.	MB0	No mutation	Asthma
U.T.	MB2	No mutation	Asthma
B.K.	MB0	No mutation	ILD Resistant Cryptococcus Splenomegaly, cytopenia Lymphoproliferation Growth retardation
D.A.	MB0	No mutation	ILD IBD Growth retardation Splenomegaly, cytopenia Resistant Giardia
R.K.	MB0	No mutation	Asthma
AS.Ş.	MB0	No mutation	Bronchiectasis
SN.Y.	MB2	No mutation	Asthma
HE.E.	MB2	No mutation	Asthma
M.T.	MB2	No mutation	Bronchiectasis IBD Resistant Giardia
S.D.	MB0	No mutation	Bronchiectasis IBD Splenomegaly Growth retardation
MK.Y.	MB0	No mutation	Asthma
I.K.	NA	No mutation	ILD Autoimmunity Lymphoproliferation Splenomegaly, cytopenia
T.G.	MB1	No mutation	Asthma
A.E.	MB0	No mutation
B.A.	MB2	No mutation
N.K.	MB0	No mutation
I.A.	MB2	Positive (c.515 G>A(p.C172Y) homozygote)
C.D.	MB2	No mutation	Growth retardation IBD Resistant Giardia
R.T.	MB0	Positive C104R heterozygote	Lymphoproliferation
ME.T.	MB0	No mutation
E.K.	MB2	No mutation
P.A.	MB2	Positive (heterozygote p.A181E(c.542C>A)
M.S.	MB2	Positive (P21Aheterozygote)
E.M.	MB2	Positive (c.512 T>G(L171R) heterozygote)
S.Y.	MB0	No mutation
B.S.	MB2	No mutation
E.O.	MB1	Positive (c.579C>A(p.C193X) homozygote)
K.H.	MB1	Positive (heterozygote C298 ihsT(pC100Lfs’6)

ILD – interstitial lung disease, IBO – inflammatory bowel disease, NA – not applicable